{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.52","value":"1.8"},{"groupId":"OG001","spread":"0.53","value":"0.5"},{"groupId":"OG002","spread":"0.51","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.57","value":"1.7"},{"groupId":"OG001","spread":"0.58","value":"0.7"},{"groupId":"OG002","spread":"0.56","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"84"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.55","value":"2.6"},{"groupId":"OG001","spread":"0.54","value":"1.8"},{"groupId":"OG002","spread":"0.54","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.60","value":"3.3"},{"groupId":"OG001","spread":"0.60","value":"3.3"},{"groupId":"OG002","spread":"0.59","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.56","value":"3.2"},{"groupId":"OG001","spread":"0.55","value":"3.6"},{"groupId":"OG002","spread":"0.54","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"82"}],"units":"Participants"}],"title":"Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.57","value":"3.6"},{"groupId":"OG001","spread":"0.57","value":"3.8"},{"groupId":"OG002","spread":"0.57","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"70"}],"units":"Participants"}],"title":"Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.53","value":"4.3"},{"groupId":"OG001","spread":"0.54","value":"4.0"},{"groupId":"OG002","spread":"0.52","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"69"}],"units":"Participants"}],"title":"Cycle 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.56","value":"3.8"},{"groupId":"OG001","spread":"0.57","value":"4.0"},{"groupId":"OG002","spread":"0.55","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"70"}],"units":"Participants"}],"title":"Cycle 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.62","value":"4.0"},{"groupId":"OG001","spread":"0.63","value":"4.0"},{"groupId":"OG002","spread":"0.59","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"Cycle 19"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.59","value":"4.6"},{"groupId":"OG001","spread":"0.59","value":"3.9"},{"groupId":"OG002","spread":"0.55","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"title":"Cycle 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.55","value":"4.2"},{"groupId":"OG001","spread":"0.56","value":"4.0"},{"groupId":"OG002","spread":"0.52","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"59"}],"units":"Participants"}],"title":"Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.58","value":"4.0"},{"groupId":"OG001","spread":"0.60","value":"5.0"},{"groupId":"OG002","spread":"0.55","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"title":"Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.56","value":"4.5"},{"groupId":"OG001","spread":"0.56","value":"4.8"},{"groupId":"OG002","spread":"0.52","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"title":"Cycle 27"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.66","value":"4.0"},{"groupId":"OG001","spread":"0.66","value":"5.3"},{"groupId":"OG002","spread":"0.59","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"title":"Cycle 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.57","value":"4.8"},{"groupId":"OG001","spread":"0.58","value":"4.8"},{"groupId":"OG002","spread":"0.52","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"51"}],"units":"Participants"}],"title":"Cycle 31"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.66","value":"3.9"},{"groupId":"OG001","spread":"0.67","value":"5.1"},{"groupId":"OG002","spread":"0.59","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"title":"Cycle 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.61","value":"4.5"},{"groupId":"OG001","spread":"0.62","value":"5.0"},{"groupId":"OG002","spread":"0.56","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"52"}],"units":"Participants"}],"title":"Cycle 35"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"98"},{"groupId":"OG002","value":"108"}],"units":"Participants"}],"description":"The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.\n\nChange from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.\n\nDRS was not included in the fixed-sequence testing procedure.","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve \\[AUC\\] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.","id":"OG000","title":"Placebo + Carboplatin + Paclitaxel -> Placebo"},{"description":"Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.","id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel -> Placebo"},{"description":"Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.","id":"OG002","title":"Veliparib + Carboplatin + Paclitaxel -> Veliparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"BRCA-mutation population, participants with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35","title":"Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population","type":"SECONDARY","unitOfMeasure":"score on a scale"}